The retinal device will be offered to late-stage retinitis pigmentosa (RP) patients in six German university clinics and teaching hospitals.
Retina Implant CEO Walter-G Wrobel said: "Since receiving CE mark of our Alpha IMS microchip, we have been focused on educating and partnering with physicians across the EU. Obtaining this reimbursement was a critical next step as we continue our mission to restore vision to patients with RP."
Alpha IMS is implanted beneath the retina in the macular region and simulates the functioning nerve cells of the eye.
The device helps RP patients to recognize facial expressions, distinguish objects such as telephones, cups, plates and read signs on doors.
Pro Retina Germany chairman Franz Badura said: "NUB innovation payments are an important way to introduce new therapies, under carefully controlled conditions, to help ensure patients receive treatment safely.
"The creation of retinal implants is something that we’ve worked quite closely with Retina Implant to develop, making this victory even more gratifying."